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Clostridium difficile associated disease is fundamentally associated with dysbiosis of the gut microbiome
as a consequence of antibiotic use. This is because this sporulating, obligate anaerobe germinates and
proliferates rapidly in the dysbiotic gut, which is an indirect consequence of their use. During its growth,
C. difficile produces two toxins, toxin A (TcdA) and toxin B (TcdB), which are responsible for the majority
of clinical symptoms associated with the disease. Three parenterally delivered vaccines, based on detox-
ified or recombinant forms of these toxins, have undergone or are undergoing clinical trials. Each offers
the opportunity to generate high titres of toxin neutralising antibodies. Whilst these data suggest these
vaccines may reduce primary symptomatic disease, they do not in their current form reduce the capacity
of the organism to persist and shed from the vaccinated host. The current progress of vaccine develop-
ment is considered with advantages and limitations of each highlighted. In addition, several alternative
approaches are described that seek to limit C. difficile germination, colonisation and persistence. It may
yet prove that the most effective treatments to limit infection, disease and spread of the organism will
require a combination of therapeutic approaches. The potential use and efficacy of these vaccines in
low and middle income countries will be depend on the development of a cost effective vaccine and
greater understanding of the distribution and extent of disease in these countries.
 2019 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. An overview
1.1. The disease and pathogen
Clostridium difficile is the leading cause of healthcare-associated
diarrhoeal disease in the developed world [1], and a major cause of
community-associated infection (CAI) [2]. This organism, which is
found naturally in the gastrointestinal tracts of many domesticated
animals, and consequently the environment [3,4], is strongly asso-
ciated with disease in patients with increasing age and frailty [5],
immunodeficiency and in particular modification of the normal
microbiota through antibiotic use [6]. Extended stay in healthcare
facilities is associated with an increased risk of disease, with infec-
tion linked to localised environmental contamination with
metabolically inactive spores that are resistant to most cleaning
protocols [7]. Elderly patients treated with antibiotics are particu-
larly vulnerable as such treatments modify the composition andcomplexity of the intestinal bacterial population [8]. Loss of micro-
biome diversity as a consequence of antibiotic use has been linked
to a reduced capacity to process and modify primary bile salts
(including taurocholate and cholate) to their secondary state and
these are reabsorbed. Loss of organisms that perform this function
results in failure to process these compounds resulting in increased
concentrations of primary bile salts, which act as germinants for C.
difficile spores. Further, as secondary bile salts inhibit C. difficile
vegetative growth, their loss is significant in disease progression
[9]. Clinically, infection varies from asymptomatic carriage to mild,
single episode infections, through to severe, recurrent and dis-
abling disease. Rates of morbidity and mortality differ widely,
reflecting differences in both host vulnerability and the genetic
composition of the infecting bacterium.
Disease is largely associated with the production of two large
glucosyltransferase exotoxins, Toxin A (TcdA) and Toxin B (TcdB)
[10,11] that modify the cellular architecture of the epithelial sur-
face of the colon through interactions with members of the super-
family of Rho GTPases [12] that are involved in maintenance of cell
cytoskeleton. The resulting loss of integrity of epithelial cells of theoi.org/
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induces a prolific inflammatory response including an influx of
high numbers of polymorphonucleocytes (PMNs). Whilst symp-
toms can be alleviated through treatment with metronidazole,
fidaxomicin and vancomycin, which destroy the toxin-producing
bacteria, further complications including pseudomembranous col-
itis, toxic megacolon and sepsis also occur in a number of cases.
TcdA and B are highly homologous, multi-domain proteins whose
structure and function are well described [13,14]. The genes for
TcdA and B (tcdA and tcdB) are encoded on a 19.6 kB pathogenicity
island and amplification of sequences within this locus has identi-
fied multiple ‘toxinotypes’ [15]. In general, differences are associ-
ated with point mutations in the catalytic domain of TcdB and
deletions in the C-terminus of TcdA. Naturally occurring PaLoc neg-
ative strains exist and have been used effectively to restrict coloni-
sation with toxin producing strains [16]. However, the observation
that the genes encoding these toxins are linked to mobile genetic
elements [17] has raised concerns that acquisition of these genes
by non-toxic strains can add to disease burden. The relative
contribution of each toxin in disease has been the subject of some
controversy, with early studies indicating TcdA alone was respon-
sible for diarrhoeal symptoms [10]. However, recent re-evaluation
suggests that TcdB is a key factor in C. difficile disease severity [11].
In addition, a small but clinically relevant number of strains
encode a third toxin, commonly referred to as C difficile binary
toxin (CDT) [18]. This toxin is composed of two domains, an enzy-
matically active A component (CDTa), which causes ADP-
ribosylation of G-actin, and a cell-binding and translocation B com-
ponent, CDTb. CDT alone does not induce severe disease in a ham-
ster [19] or mouse model of CDI [20] but appears to enhance
colonisation [21] and contribute to virulence [22] Although the
biological role of CDT in infection appears to be adjunctive,
enhanced protection in preclinical vaccine trials following inclu-
sion of this antigen was seen [23].
1.2. Current diagnosis and treatment
New technologies that allow rapid diagnosis of infection have
largely replaced microbiological culture of the organism, although
culture currently remains a requirement for molecular epidemio-
logical investigations. Detection depends on recognition of two tar-
gets; glutamate dehydrogenase (GDH), a common conserved
antigen in C. difficile and the A and B toxins (or genes) (most fre-
quently but not exclusively TcdB) in diarrheal stool samples [24].
These antigens or genes are recognised through the use of specific
antibodies in commercial EIA based tests or amplification of speci-
fic sequences through nucleic acid amplification tests or NAAT. Ide-
ally, identification of a positive sample initiates an algorithmic
approach to confirm diagnosis. Metronidazole and vancomycin
remain first line drugs for treatment of confirmed disease (if simple
withdrawal of the inciting antimicrobial cannot be done), with
metronidazole typically prescribed for mild disease and van-
comycin for severe disease [25]. Recovery can be complicated by
recurrence of symptomatic disease following completion and with-
drawal of antibiotic treatment. Persistence of dysbiosis within the
gut is thought to support germination of either resident spores or
spores from the contaminated environment. Typically, patients
that suffer one recurrence have a significant risk of enduring fur-
ther and frequently multiple recurrences [26]. Fidaxomicin,
recently introduced as an alternative treatment to the standard
antibiotics, offers a reduced risk of recurrence as it has less impact
on the normal microbiota [27]. However, its high cost is limiting
widespread use. In patients who suffer multiple recurrences, a fae-
cal transplant can be a highly effective treatment [28,29]. Stools
provided from a healthy ‘donor’ and introduced via the upper or
lower gastrointestinal tract allow the diversity of gastrointestinalPlease cite this article as: T. V. Riley, D. Lyras and G. R. Douce, Status of vaccine
10.1016/j.vaccine.2019.02.052microbiota to re-establish, limiting further growth of C. difficile
and eliminating symptoms [30].
1.3. Economic burden of disease
The global increase in incidence and severity of C. difficile infec-
tion (CDI) over the past 20 years reflects a combination of factors
including the greater use and misuse of antibiotics, a larger vulner-
able population as mean average age increases and a greater
awareness and diagnosis of disease. Studies performed in North
America and Europe have reported two- to four-fold increased inci-
dence of CDI in the past decade. In the United States, alone, an esti-
mated 453,000 new cases of CDI arise per year, with the infection
linked directly to approximately 29,000 deaths within 30 days of
diagnosis of CDI [31]. In direct comparisons between patients with
and without CDI, the resultant increased in hospital stay elevated
hospital costs (3.5-fold) with patients six times more likely to die
as a consequence of infection. Reports from United States National
Vital Records reveal that from 1999 to 2008 death certificates list-
ing C. difficile enterocolitis as the primary cause of death increased
from 793 to 7483 with the majority of deaths from CDI occurring in
persons >65 years of age [32]. The economic burden of this disease
is thus significant [31] (multi-billion dollars in healthcare costs)
and set to rise further as life expectancy in developing countries
increases. This is not a problem limited to the US and Europe. In
Korea, the prevalence of C. difficile increased from 1.43 cases per
10,000 in 2008 to 5.6/10,000 in 2011, with an increased economic
burden over that time of $13.4 million [33]. In Australia, a large-
scale study using data from 89 hospitals within Victoria reported
6736 cases of CDI between Oct 2010 and Dec 2014; rates were
comparable to those in the US and Europe. Of these, 4876 cases
(2.49/10,000 occupied bed days) were linked to hospital stay, with
the remaining linked to community associated infections CAI [34].
In this study, severe disease was significantly higher in CAI with
links to food contaminated with the epidemic outbreak strain
[35]. This observation further supports the increased need for
surveillance of disease within both the hospital and community
settings.
1.4. Geographical distribution
Traditionally, CDI has been largely a disease of the hospitalised
elderly, although the extent and impact of C. difficile disease has
predominantly been limited to descriptions from high income
countries (HICs). This is because there are very few reliable and
quantitative countrywide evaluations of C. difficile disease in most
low and middle-income countries (L + MIC). This failure was
recently highlighted by a systematic review of the literature, which
combined key terms ‘Clostridium difficile’, ‘C. difficile’, antibiotic
associated colitis and pseudomembranous colitis, with countries
recognised as low and middle human development index (LMHDI)
countries by the United Nations Development Programme [36]. Of
the 150 studies identified using this approach between Jan 2000
and Mar 2016, 125 were excluded on grounds of relevance and lack
of demographic information. Of the remaining 25, 20 (80%) were
observational and over half were conducted in India. Only 4/25
studies were multi-institutional. Individual studies within particu-
lar hospitals in Asian countries such as Indonesia [37], Thailand
[38] and South Korea [39] suggested the organism is widespread
and capable of causing clinical disease, although given the wide-
spread availability of antibiotics, the number of cases was lower
than expected. In sub-Saharan Africa, carriage of toxigenic strains
linked to diarrhoeal disease, antibiotic usage and HIV status have
been reported in the few studies that have been performed [40].
This paucity of epidemiological data from these countries makes
extrapolation of the impact of vaccine introduction difficult toresearch and development for Clostridium difficile, Vaccine, https://doi.org/
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our knowledge that needs to be addressed rapidly. This informa-
tion will provide an accurate understanding of disease burden
within these countries but will also be essential for deciding
whether widespread vaccination is warranted for which patients
and at what age. More significantly, understanding the baseline
of infection is essential for determining the impact of vaccine
introduction. However, this will require standardisation of terms
and sampling techniques to ensure comparative analysis is valid.
Further, greater understanding of epidemiology within these coun-
tries should be supported by the use of a sensitive and repro-
ducible typing system. This will eliminate issues associated with
the use of different typing methods (pulse field electrophoresis,
restriction endonuclease analysis and PCR ribotyping) that have
been previously employed in different countries [41].
Over the last 10 years, the epidemiology of CDI has changed
dramatically with the emergence of several ‘hyper-virulent’ ribo-
types including the BI/NAP1/027, which have been associated with
significant outbreaks globally [42]. Enhanced pathogenicity and
risk of infection has been linked to a variety of factors including
the production of binary toxin [22] and resistance to fluoro-
quinolones [43]. Strains with similar features and associated with
high incidence of severe disease have also emerged in other coun-
tries, including ribotype 244 (RT244) in Australia [44] and RT176 in
Eastern Europe [45]. Both of these RTs belong to the same genetic
clade (clade 2) as RT027 but are distinct from RT027 strains.
Although modification of prescribing policies can significantly
reduce the number of outbreaks [46] associated with ribotype
027 in particular, and infections more generally (55,000 infections
in 2008 to less than 10,000 in 2013), less prevalent but clinically
relevant ribotypes have emerged and are becoming dominant in
several countries in Europe. These include RTs 056, 078 and 126
that are commonly associated with infections in farm animals
[47]. Changes in clinically relevant types may additionally reflect
the significant rise in CAI, which comprises more than 40% of all
cases in some studies [48]. Interestingly, within individual coun-
tries, particular types appear to dominate, for example 017 isolates
account for 20% of Shanghai isolates whilst in Stockholm, 005
strains are prevalent [49]; in Scotland 078 isolates account for over
10% of infections [50]. Recent studies performed in large tertiary
hospitals in Malaysia [51], Indonesia [52] and Thailand [38] under-
line the importance of using a combined diagnostic approach. In
these studies non-toxic strains and those expressing only TcdB
were identified when a combination of immunoassays for detec-
tion of glutamate dehydrogenase (GDH) and TcdA/B were used.
These data highlighted the prevalence of the 017 ribotype in Asia
[53,54] and draw attention to the presence of non-toxigenic C. dif-
ficile in this population. In summary, these data suggest local or
regional circulation of particular ribotypes implying that infection
may be a consequence of an unidentified reservoir of infection.
Furthermore, antibiotic resistance, both intrinsic and associated
with acquisition of specific genes, appears to be increasing, with
high levels of resistance to fluoroquinolones associated with the
global spread of the BI/NAP1/027 [42] strain. However, more con-
cerning is the reported observation of resistance to metronidazole
[55] and vancomycin, which are the front line treatments for this
infection [56]. These reports highlight and focus our vulnerability
with respect to treatment options and are very much associated
with the drive to develop an effective vaccine against this disease.
1.5. Target groups for vaccination
Increasing age, exposure to antibiotics and long-term stay
within a health facility are all risk factors associated with CDI.
There is also some evidence that pregnant women and some chil-
dren are vulnerable to this infection [57] possibly reflecting greaterPlease cite this article as: T. V. Riley, D. Lyras and G. R. Douce, Status of vaccine
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bility. One problem associated with vaccination of the elderly is
immune senescence that can cause impaired recognition of anti-
gens. This can make vaccination of this vulnerable population par-
ticularly difficult.2. Overview of current efforts: status of vaccine research and
development activities
2.1. Toxin based vaccines
Protection against symptomatic (diarrhoeal) disease is depen-
dent on the production of high levels of neutralising antibody to
both TcdA and TcdB [58]. In general, high levels of systemic anti-
bodies to TcdA correlatewith protection from diarrhoeawhilst neu-
tralising antibodies to TcdB reduce disease severity and recurrence
[59,60]. As such vaccines with the capacity to generate strong neu-
tralising activity to both toxins offer an opportunity to reduce
symptomatic disease. However, in animal models these vaccines
do not appear to prevent colonisation of the organism or onward
transmission through shedding of the organism in the stool [61].
Several vaccines that have completed, or are currently undergo-
ing, clinical evaluation in humans are outlined in Table 1 with
detailed descriptions given below.
2.1.1. Sanofi Pasteur toxoid vaccine
Until October 2017, the most advanced vaccine formulation in
human trials was a toxoid-based vaccine produced by Sanofi Pas-
teur. This vaccine had been tested in several clinical phase I
(NCT00214461, NCT00127803, NCT00772954) and II trials
(NCT01230957, NCT00772343), and a large scale phase III trial
was initiated in October 2013 (NCT01887912). This vaccine con-
tained formalin-inactivated preparations of TcdA and TcdB, puri-
fied from the naturally high toxin producing C. difficile strain
VP110463, admixed with AlOH3 adjuvant. In reported phase II
studies (June 2011–2013), approximately 90% of patients (aged
40–64) showed high levels of neutralising activity when immu-
nised on 3 occasions (0, 7 and 30 days) with 100 lg total antigen.
A subsequent open labelled study in the older patients (aged 65–
75 years of age) revealed an approximate 60% conversion rate
which could be enhanced to approximately 90% following a fourth
boost on day 180 [62]. The manufacture of these vaccines at global
scale was considered achievable, given that it was based on con-
ventional and proven methodologies. However, following primary
interim reporting of phase 3 data, it was concluded that the pri-
mary objective, the prevention of primary CDI, was unlikely to be
achieved. This has resulted in the entire programme of vaccine
development within Sanofi Pasteur being halted. This significantly
changes the landscape in vaccine development as failure, at this
relatively late stage in development, has implications for the
remaining vaccines currently undergoing clinical evaluation that
are also based on similar approaches. These approaches are
described as are other approaches, the value and importance of
which may gain increased attention in this changing climate
2.1.2. Pfizer genetically detoxified toxin vaccine
In contrast to the Sanofi Pasteur vaccine, this formulation con-
tains modified versions of both TcdA and TcdB with reduced toxi-
city as a consequence of amino acid substitutions in the
glucosyltransferase domains of both toxins (D285A/D287A for
TcdA; D286A/D288A for TcdB) [63]. These toxins are generated
from an episome expression vector used to transform a non-
sporulating C. difficile that lacks the tcdA and tcdB genes [63]. Anal-
ysis of these recombinant proteins revealed a low level of residual
toxic activity, requiring the proteins to be additionally chemicalresearch and development for Clostridium difficile, Vaccine, https://doi.org/
Table 1
Development status if current vaccine candidates.
Candidate Name/identifier Developer/manufacturer Approach Phase of
development
References/
clinical trial ID
Cdiffense Sanofi/Pasteur Chemically detoxified TcdA and TcdB Terminated at phase III NCT 01,887,912
Ref. [62]
PF-06425090 Pfizer Genetically and chemically detoxified TcdA and TcdB Phase III NCT03090191
Ref. [63,64]
VLA84 Valneva Recombinant chimeric protein linking the binding
domains of TcdA and TcdB
Phase II NCT02316470
Ref. [65]
VP20621 Shire Mucosally delivered, live non toxigenic strain of C. difficile Phase II NCT01259726
Ref. [16]
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were safe and highly immunogenic, generating strong and sustain-
able neutralising activities in both 40–64 and 65–75 age groups
with antigen alone vaccines more potent han those containing
the Al(OH)3 adjuvant (NCT 01706367) [64]. This vaccine was
granted fast track designation by the FDA in 2014 and, based on
interim reporting of data from a phase II study looking at the
impact of an accelerated and non-accelerated immunisation sched-
ule of responses in individuals aged 65–85 (NCT02561195), a
phase III study to establish the impact of the vaccine on primary
CDI was initiated in early 2017 (NCT03090191). Results from this
study are expected in the third quarter of 2020, with data on the
incidence of recurrence following vaccination being included as a
secondary measurement of efficacy in this trial.2.1.3. Valneva recombinant chimeric vaccine VLA84
In contrast to the toxoided vaccines, the Valneva vaccine is
based on a recombinant chimeric protein, designed to capture neu-
tralising epitopes of both toxins within a single protein. This
approach avoids issues associated with residual toxicity by genet-
ically fusing the binding (C-terminal) domains from both toxins
(TcdA, 15 of 31 repeats; TcdB 23 of 24 repeats) via a short linking
sequence of 12 amino acids. Consequently this vaccine can be gen-
erated in heterologous expression systems avoiding the need for C.
difficile culture. This vaccine is anticipated to be less complex to
manufacture than the equivalent toxoided vaccines. In phase I
studies (NCT01296386), unadjuvanted antigen appeared as
immunogenic as adjuvanted formulations. Antibodies raised to
these antigens were able to neutralise the activity of both native
toxins produced by VPI10463 [65]. This data has been confirmed
in a successful phase II study (NCT02316470) in two cohorts of
patients (aged 50–64/aged 65+).
One disadvantage of this chimera is that it lacks several neutral-
ising epitopes that have been located elsewhere in the toxin
[66,67]. This includes epitopes within the glucosyltransferase
domain that are not included in the chimera. Also it does not target
the other host receptor binding regions identified in TcdB, which
facilitate uptake of the toxin independently of the C-terminal
repeat region [68]. Further, some isolates of C. difficile express vari-
ants of TcdB with amino acid substitutions in the binding domain,
which may limit the capacity of this vaccine to be effective against
diverse clinical isolates [69,70]. The relevance of this variation with
respect to neutralising activity is unclear at present but should be
considered, especially for those vaccines based on the binding
domains alone.2.2. Pre-clinical consideration of additional vaccine antigens
2.2.1. Addition of CDT
Several strains of C. difficile, including many associated with
outbreaks or greater severity of disease (ribotypes 027, 078, 244),
encode a third toxin, CDT. Combining this antigen within toxoidedPlease cite this article as: T. V. Riley, D. Lyras and G. R. Douce, Status of vaccine
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when compared to vaccines based only on TcdA and TcdB [23].
Whilst inclusion of this antigen offers an opportunity to improve
the response to a number of clinically important strains, including
the epidemic 027 ribotype, its late identification as a vaccine can-
didate may limit its inclusion in those vaccines likely to be licensed
in the next 5 years.
2.2.2. Addition of vaccine antigens to limit colonisation
Prevention of primary CDI is the stated objective of all of the
current vaccines undergoing clinical evaluation. Success in this
context is determined by production of toxin neutralising antibod-
ies and the absence of diarrheal disease. However, data from ani-
mal models suggests that protected animals continue to shed the
organism for up to 3 weeks post infection [61]. Therefore, use of
a vaccine that prevents toxin-mediated symptoms but does not
limit germination, outgrowth, sporulation and release of the spores
into the environment could indirectly result in increased transmis-
sion. Further, if diagnosis of infection is partly reliant on detection
of toxin in the faeces, its neutralisation may lead to under-
reporting of cases. An ideal vaccine should therefore be formulated
to include bacterial factors that target germination, colonisation or
sporulation. Several antigens have been proposed and tested pre-
clinically, including several surface exposed cell wall proteins.
These include SlpA, Cwp66, Cwp84 and flagellar antigens, which
have been identified as being actively involved in early colonisa-
tion of the gut [71,72]. Whilst all appear to be immunogenic, in
preclinical testing none has generated high levels of protection
against C. difficile colonisation or disease [73,74].
2.2.3. Use of non-toxigenic strains of C. difficile to limit disease
The potential of non-toxigenic strains, delivered mucosally to
limit primary and recurrent disease, has been evaluated pre-
clinically, with impact on recurrent disease determined clinically
(NCT01259726) [16]. This approach offers direct competition for
the colonisation niche within the host and can easily be used in
L + MICs. Administration of this vaccine was well tolerated and
reduced recurrence from 30% in patients receiving the placebo
compared to 11% receiving the vaccine (odds ratio [OR], 0.28;
95% CI, 0.11–0.69; P = .006). This vaccine is attractive as it offers
the opportunity to stimulate mucosal responses that may limit
colonisation. However, the observation that the toxin genes can
be acquired via horizontal gene transfer raises the concern that this
approach may result in evolution of new toxigenic strains [17].
2.2.4. Spore coat proteins as vaccine candidates
Several proteins located within the exosporium coat of C. diffi-
cile including CotA, CotE, CdeC and CdeH have been identified as
possible vaccine targets [75]. It is predicted that generation of anti-
bodies to these proteins may offer a combined impact, encouraging
uptake and destruction of spores prior to germination, and limiting
efficient sporulation and excretion from the host [76].research and development for Clostridium difficile, Vaccine, https://doi.org/
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Whilst systemically generated anti-toxin responses reduce or
eliminate toxin-associated symptoms, activation of mucosal
responses at the immediate site of infection may reduce symptoms
through the prevention of toxin action within the gut. One
approach that has shown preclinical success is the oral delivery
of recombinant B. subtilis spores expressing fragments of TcdA,
which limited colonisation and disease in hamsters [77]. Further
protection was associated with high levels of toxin specific sIgA
in the faeces of these animals highlighting the importance of
mucosal response in protection.
2.2.6. Carbohydrate-based vaccines
Three phosphorylated polysaccharides; PSI, PSII and PSIII, first
revealed during structural analysis of the C. difficile cell wall have
also been considered as potential vaccine candidates [78]. In par-
ticular PSII, a common antigen to many strains, appears immuno-
genic with antibodies to this antigen found in the stools of
naturally infected horses and man [79]. Experimental synthetic
vaccines generated through conjugation to diphtheria toxoid
(crm197) or recombinant fragments of generate high level of PsII
specific antibody in mice and farm animals [80,81]. Whilst these
antibodies recognise C. difficile vegetative cells in culture, their
capacity to protect against primary CDI remains unclear.3. Therapeutic approaches for primary and recurrent disease
Whilst effective vaccination offers an opportunity to prevent
symptomatic disease, several alternative prophylactic and thera-
peutic approaches are undergoing clinical and preclinical evalua-
tion. Although adoption of some of these approaches may be
limited by cost and lack of infrastructure, the opportunities they
offer should be considered in the context of effective vaccine
development.
3.1. Microbiome modification
Whilst prevention of disease should be the key objective of any
vaccine, prevention of recurrent disease, which places a further
financial burden on the healthcare system of any individual coun-
try, should be considered. In this context, our increasing knowl-
edge of functional activity of particular bacteria within the
microbiome would suggest that treatments based on replacement
of key members of the gut microbiota are feasible. Whilst faecal
microbiota transplantation (FMT) is reported to be clinically effec-
tive [28,30], the unpleasant nature of the procedure and the level
of screening required to ensure the transplant is free from signifi-
cant enteric pathogens continue to limit its use therapeutically. In
the future, identification of key organisms with specific metabolic
functions will allow specific combinations of bacteria to be pre-
pared. Such an approach is effective at limiting colonisation in
mice [82] but similar combinations for treatment of human disease
have still to be evaluated. Currently, 41 clinical trials to evaluate
the effectiveness of FMT for C. difficile are ongoing. Most are
focussed on modes of delivery; fresh versus frozen samples, impact
of encapsulation and use of defined bacterial formulations. Rebi-
otix, who have focussed on the commercialisation of this approach,
have completed a phase 2 open label study using a standardised
microbiota suspension (RBX2660) (NCT01923417). This trial
reported 87% efficacy in 31 patients 6 months after treatment with
bacterial suspension delivered by enema. This formulation pre-
vented recurrence in 50% of patients following a single treatment
and in 87% of patients after a second dose [83]. Whilst this
approach has potentially wide application, some caution is war-
ranted regarding its widespread application in patients whose gen-Please cite this article as: T. V. Riley, D. Lyras and G. R. Douce, Status of vaccine
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number of links that are being made between microbiome compo-
sition and conditions such as diabetes, obesity and mental health
issues [84–86].
3.2. Antibody therapy
An alternative approach to treatment of recurrent disease is the
direct infusion of humanised monoclonal antibodies capable of
neutralising toxin activity. Merck have pioneered this approach
and clinical trials using their monoclonal antibody formulations
Bezlotoxumab (raised to TcdB) and Actoxumab (raised to TcdA)
have been completed (NCT00350298, NCT01241552). Results from
phase II clinical studies (NCT00350298) showed that a single infu-
sion of the Bezlotoxumab antibody given in conjunction with stan-
dard metronidazole or vancomycin treatment reduced the
recurrence of C. difficile recurrence compared to antibiotic treat-
ment alone [87]. In contrast, use of actoxumab alone did not
appear to show any clinical benefit. These results have been sup-
ported by data produced in recent phase III trials
(NCT01241552), in which treatment with Bezlotoxumab compared
to the placebo-controlled group reduced recurrence by around 10%
[88]. However, as administration of this intravenous treatment will
require specialist healthcare facilities, generation of antibodies is
likely to be costly and its efficacy limited, it is unlikely to become
a routine treatment for most patients.
An alternative approach is the use of orally delivered
colostrum-derived antibodies, which are generated by immunisa-
tion of pregnant cows with spores, vegetative cells and TcdB puri-
fied from C. difficile [89]. In preclinical evaluation of mouse
infection and relapse models, administration of these antibodies
prevented 80% of primary CDI and reduced disease recurrence by
67%.
3.3. Phage/phage tails
Several bacteriophages with lytic activity to C. difficile have been
identified and studied in preclinical studies [90,91]. Phages are
attractive as therapeutics as their specificity ensures minimal dis-
ruption and loss of diversity within the microbiome. Whilst cur-
rently identified natural phages encode integrases, which limit
their long-term lytic effectiveness, the potential to genetically
modify such phages to improve efficacy is promising. An alterna-
tive approach is the use of C. difficile R type bacteriocins, which
resemble Myoviridae phage, structurally encoding a contractile
sheath, a nanotube core and tail fibers. However, instead of deliv-
ering DNA across the bacterial membrane, injection of the nan-
otube core disrupts the cell membrane potential and kills the
cell. These protein antibiotics are effective in mouse models at
reducing the number of organisms persisting in the gut [92]. Fur-
ther, these proteins can be manipulated to redirect their specificity
using phage sequences from existing lysogenic phages within the
genome. As a consequence, recombinant versions have been gener-
ated with killing activity against the majority of current clinical
types [93].4. Likelihood for vaccine implementation
Given the extent of testing of the vaccines currently in clinical
trials, it is feasible that a licensed C. difficile vaccine may be avail-
able within the next 5 years. However, this will depend on the
demonstrable level of efficacy generated by the two remaining vac-
cines. Given the apparent failure of the Sanofi vaccine in phase 3
trials, it is essential that, moving forward, improvements to the
existing vaccine formulations should be considered. This mayresearch and development for Clostridium difficile, Vaccine, https://doi.org/
6 T.V. Riley et al. / Vaccine xxx (xxxx) xxxinclude the addition of further antigens that limit colonisation or
sporulation, or identification of alternative or combined treatment
regimens. Most importantly, we need to identify approaches that
limit both primary and recurrent disease burden, which will
reduce suffering and lower the economic impact on worldwide ris-
ing health-care costs. Whilst the burden of disease is currently
associated with the increasing elderly population within high
income countries (HICs), greater understanding of the extent of
disease within M + LICs will allow appropriate decisions regarding
the best approach to limit disease. Implementation of vaccine pro-
grammes or other interventional strategies will depend on the
availability and use of standardised systems of surveillance, many
of which are currently not available. In many countries, significant
organisational and financial effort will be required including the
adoption of established methodologies that allow direct correla-
tion with existing data. Building this resource now will allow more
rapid use and dissemination of effective treatments, including vac-
cines, to limit CDI.
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